We believe the rapid pace of technology-enabled innovation in healthcare creates attractive opportunities for those with the vision and experience to see them.
Focusing on the individual is the key to making healthcare effective and affordable for everyone. Innovation is critical to this transition across the industry, but it’s not an easy path. Inadequate and antiquated systems impede the adoption of new technologies. How healthcare is accessed and paid for is changing faster than consumers and providers can adapt. Life- and cost-saving solutions get lost navigating the winding paths to commercialization.
With a specialist’s grasp of healthcare’s inner workings, we anticipate industry trends and identify companies and technologies that power change. We seek growth stage companies with commercial-ready innovations that drive precision health, providing the capital and the experience to guide companies to reach their full potential.
By catalyzing the adoption of innovation, Blue Ox helps to deliver the promise of better healthcare focused on the individual.
Focusing on the individual is the key to making healthcare effective and affordable for everyone. Innovation is critical to this transition across the industry, but it’s not an easy path. Inadequate and antiquated systems impede the adoption of new technologies. How healthcare is accessed and paid for is changing faster than consumers and providers can adapt. Life- and cost-saving solutions get lost navigating the winding paths to commercialization.
With a specialist’s grasp of healthcare’s inner workings, we anticipate industry trends and identify companies and technologies that power change. We seek growth stage companies with commercial-ready innovations that drive precision health, providing the capital and the experience to guide companies to reach their full potential.
By catalyzing the adoption of innovation, Blue Ox helps to deliver the promise of better healthcare focused on the individual.
Location: United States, New York
Employees: 1-10
Founded date: 2009
Investment Stage: Series D; Series E; Series G
Portfolio 10
| Date | Name | Website | Total Raised | Location |
| 06.07.2022 | Gemelli Bi... | gemellibiotech.com | $20.85M | United Sta... |
| 05.05.2022 | MedSave US... | medsaveusa.com | - | - |
| 05.05.2022 | Healarium ... | healarium.com | - | - |
| 05.05.2022 | Delphi Beh... | delphihealthgroup.com | - | United Sta... |
| 05.05.2022 | Apollo Med... | apollomed.net | - | - |
| 13.11.2019 | Sera Progn... | seraprognostics.com | $165.3M | United Sta... |
| 12.09.2018 | Epic Scien... | epicsciences.com | $217M | United Sta... |
| - | PatientMat... | patientmatters.com | - | United Sta... |
| - | Advocate m... | advocatemymeds.com | - | United Sta... |
| - | Infinity B... | infinitybehavioral.com | - | United Sta... |
News 46
| Date | Title | Description |
| 07.12.2023 | Sera Prognostics Announces Primary Endpoint Criteria Met | Sera Prognostics Inc. today announced that the Data Safety Monitoring Board (DSMB) overseeing its pivotal Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study recommended stopping enr... |
| 19.04.2023 | Epic Sciences Announces Medicare Coverage for Breast-Cancer Focused ctDNA Gene Panel | Epic Sciences, Inc. announced today that the company’s 56-gene ctDNA panel for genomic profiling of metastatic breast cancer is covered by the MolDX program (administered by Palmetto GBA) that provides coverage under the Medicare program fo... |
| 22.06.2022 | Gemelli Biotech Completes $19 Million Series A Financing Funding to accelerate commercialization of its trio-smart® and ibs-smart® precision diagnostic tests for IBS and SIBO | Gemelli Biotech Corp. (“Gemelli”), a company focused on improving health by providing precision diagnostics for gastrointestinal (GI) diseases, today announced the completion of a $19 million Series A financing. Blue Ox Healthcare Partners ... |
| 01.06.2022 | Epic Sciences Raises $42M in First Close of Series F Financing to Advance Comprehensive Profiling for Metastatic Cancer Patients | Epic Sciences, Inc. ("Epic" or "Epic Sciences"), a privately held diagnostics company, has completed a $43 million first close of its Series F financing. The company will use the capital from this additional round of pri... |
| 28.03.2022 | Epic Sciences Unveils DefineMBC™, A Novel Blood-Based Test Designed To Improve Care For Metastatic Breast Cancer Patients | Multiple leading community cancer centers enrolling in Early Access Program DefineMBC biomarkers for ongoing characterization of patients in biopharma drug trials Epic Sciences, Inc. announces DefineMBC, a novel metastatic breast cancer (... |
| 01.02.2022 | Sera Prognostics Announces New Agreement With Multiplan, Expanding Patient Access to the PreTRM® Test | Salt Lake City – February 1, 2022 – Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today annou... |
| 30.01.2022 | Epic Sciences and Fulgent Genetics Collaborate to Deliver DefineMBC™ Results for Metastatic Breast Cancer Patients | Epic Sciences scales its workflow for ctDNA testing with Next Generation Sequencing Leader Fulgent Fulgent Genetics’ expertise in high-volume testing powers Epic’s Comprehensive Cancer Profiling Epic Sciences, Inc. today announced it has ... |
| 16.12.2021 | Epic Sciences and Biosplice Therapeutics Announce Partnership for Metastatic Cancer Trials | Comprehensive Profiling on the Epic Platform Maximizes Biomarker Analysis for Discovery and Clinical Studies Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation f... |
| 02.12.2021 | Sera Prognostics Announces Pricing for PreTRM® Test, the Only Broadly Validated Blood Test to Assess Risk of Preterm Birth | New Assigned Rate Further Validates the Commercial Value of the PreTRM® Test Salt Lake City – Dec 2, 2021 – Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innova... |
| 01.12.2021 | Sera Prognostics Announces Publication of Data Confirming the Performance of the Ibp4/shbg Biomarkers in Diverse Non-U.S. Populations | Results confirmed that a U.S. validated proteomics predictor could be applied in low and middle income countries to help address global preterm birth challenges Salt Lake City, – December 1, 2021 – Sera Prognostics Inc., The Pregnancy Comp... |
Show more
Mentions in press and media 6
| Date | Title | Description |
| 29.04.2021 | Sera Prognostics Completes $100 Million Series E Financing Led by Blue Ox and Anthem | SALT LAKE CITY, April 28, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics, Inc., The Pregnancy Company® (“Sera”), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, t... |
| 13.11.2019 | SERA PROGNOSTICS RAISES $36 MILLION SERIES D FINANCING LED BY BLUE OX HEALTHCARE PARTNERS | Two Strategic Healthcare Companies Join Investment Round Key Scientific Publication in Obstetrics & Gynecology Shows Sera is the Leading Authority in Assessing Preterm Birth Risk SALT LAKE CITY – November 13, 2019 – Sera Prognostics, ... |
| 12.09.2018 | Blue Ox Healthcare Partners Leads $52 Million Investment in Epic Sciences | NEW YORK – September 12, 2018 – Blue Ox Healthcare Partners, LLC (“Blue Ox” or the “Firm”), an investment firm focused on providing growth capital to healthcare companies in the middle market, today announced that it led a $52 million Serie... |
| 12.09.2018 | Blue Ox Healthcare Partners Leads $52 Million Investment in Epic Sciences | NEW YORK--(BUSINESS WIRE)--Blue Ox Healthcare Partners, LLC , an investment firm focused on providing growth capital to healthcare companies in the middle market, today announced that it led a $52 million Series E investment in Epic Science... |
| 06.02.2018 | Blue Ox Buys Minority Stake in RX Solutions | Blue Ox Healthcare Partners, LLC, a specialized private equity firm investing growth capital in the healthcare industry, has taken a 30% stake in RX Solutions, LLC. The business of RX Solutions is to enable consumers to gain access to fixed... |
| 06.02.2018 | Blue Ox Buys Minority Stake in RX Solutions | Blue Ox Healthcare Partners, LLC, a specialized private equity firm investing growth capital in the healthcare industry, has taken a 30% stake in RX Solutions, LLC. The business of RX Solutions is to enable consumers to gain access to fixed... |